8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Labcorp reports higher third-quarter earnings and raises 2026 guidance
Filed with the SEC on · Summarized by InvestorsBot
Labcorp’s third-quarter 2026 revenue rose 6.9% to $3.81 billion, while diluted EPS increased to $3.22 from $3.12 and adjusted EPS rose 14.5% to $4.78. The company raised its 2026 revenue-growth forecast to 5.9%-6.7% and adjusted EPS guidance to $18.30-$18.70, while announcing or closing four acquisitions, including agreements involving BioReference Health, Myriad Genetics and Millennium Health.